A project to collect and analyze data on sarcoma patients
Official title: A Prospective Registry Study on Biological Disease Profile, Intervention Type and Clinical Outcome in Adolescent and Adult Patients With Soft-tissue and Bone Sarcoma
Run by University Hospital Heidelberg · NCT04758325 · Data updated 2026-11-12
This study is collecting and analyzing information from sarcoma patients to help improve understanding and treatment of this type of cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 12 Years and up |
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | University Hospital Heidelberg Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Heidelberg, Baden-Wurttemberg) |
| Status | Recruiting |
| Started | July 23, 2019 |
| Main results expected | July 2030 |
| Study ends | December 31, 2032 |
| Registry record updated | March 25, 2025 |
| Trial ID | NCT04758325 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this project are individuals aged 12 years and older with a suspected or proven diagnosis of soft-tissue or bone sarcoma.
✕Probably not a fit
Patients with severe neurological or psychiatric disorders that impede their ability to provide informed consent may not benefit from this project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The Sarcoma Biology and Outcome Project (SarcBOP) is an observational registry designed to create a comprehensive database that encompasses various aspects of sarcoma treatment and research. It collects clinical, pathologic, and radiologic information, along with multi-layered molecular data and patient-reported outcomes. The project integrates with the clinical activities of the Heidelberg Sarcoma Center and includes a dedicated biobank for tissue samples and liquid biopsies, aiming to provide valuable resources for clinicians and researchers. By continuously updating this database, SarcBOP seeks to enhance understanding and treatment of sarcomas.
Why it matters
Potential benefit: If successful, this project could significantly improve the understanding and treatment options for patients with sarcoma.
How similar studies have gone: Other studies focusing on comprehensive data collection in rare diseases have shown promise, indicating that this approach could yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Suspected or proven diagnosis of soft-tissue or bone sarcoma (STBS) * Age ≥12 years * Ability to understand nature and individual consequences of the registry * Written informed consent * Subjects who are physically or mentally capable of giving consent Exclusion Criteria: • Severe neurological or psychiatric disorder interfering with the ability to give written informed consent
Where it's running
-
National Center for Tumour Diseases, University Hospital Heidelberg
Heidelberg, Baden-Wurttemberg, Germany Recruiting
Study contacts
- Principal investigator: Richard F. Schlenk, Prof.Dr.med — National Center for Tumour Disease
- Study coordinator: Richard F. Schlenk, Prof.Dr.med
- Email: richard.schlenk@med.uni-heidelberg.de
- Phone: +49 6221 56 6228
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sequential CD146- and HER2-targeted CAR T-cell therapy for advanced sarcoma
This treatment will test whether giving a patient's own CAR T cells that target CD146 and HER2, one after the other, can shrink tumors in children and adults with relapsed or refractory advanced sarcoma.
-
MIGHTY: CAR T cells targeting B7-H3 for pediatric, teen, and young adult sarcoma
This Phase 1 trial tests autologous hBRCA84D CAR T cells in kids, teens, and young adults (1–24) with relapsed or refractory RMS, ES, or DSRCT to see if the therapy is feasible and safe.
-
Lifileucel (Tumor-infiltrating lymphocytes) for advanced soft tissue sarcoma
This study tests lifileucel, a cell therapy made from a patient’s own tumor cells, in adults with unresectable or metastatic soft tissue sarcoma who have had prior treatments to see if it helps shrink tumors and improve outcomes.
-
Domatinostat with Sirolimus for relapsed or refractory sarcoma and osteosarcoma
This study tests whether the cancer drugs domatinostat and sirolimus together can help adolescents and adults whose sarcoma or osteosarcoma has come back or stopped responding to standard therapy.
-
Clonal Hematopoiesis Effects with Chemo and Radiation in Solid Cancers
This study tests whether clonal hematopoiesis affects outcomes for adults with solid cancers who are receiving chemotherapy or radiation.
-
AYA Sarcoma Survivors: Personalized Exercise Program Pilot
This pilot tests a personalized 12-week exercise program for adolescents and young adults with sarcoma to see if a triage tool can connect them with the right rehabilitation and exercise services.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.